AlphaMol
AlphaMol is a biopharmaceutical company operating across Switzerland and China that uses its proprietary AI-driven GPCR-Discovery platform to develop drug candidates for autoimmune, metabolism, and pain conditions, targeting pharmaceutical partnership and licensing deals.
- Company typePrivate
- Founded2020
- HeadquartersShenzhen, China
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What AlphaMol does
AlphaMol is a biopharmaceutical company founded in 2020 and headquartered in Allschwil (Basel), Switzerland, with regional offices in Shanghai and an R&D office in Shenzhen, China. The company operates a dual-entity structure consisting of AlphaMol Science Ltd. (Switzerland) and Alpha Molecular Technology Co., Ltd. (China). Its core business is G-protein-coupled receptor (GPCR)-targeted drug discovery and development, supported by the proprietary GPCR-Discovery AI platform that integrates computational biology, artificial intelligence, and biotechnology across modules including GPCR-GPT (target identification), GPCR-3D (structure prediction), Alpha-screen (functional screening), GPCRomx (ligand selectivity), GPCR-lead (optimization), GPCR-XDC (peptide-drug conjugate design), and AlphaE (binding energy prediction with validated 1 kcal/mol RMSE).
The company's pipeline includes AM-001, an oral small molecule targeting MRGPRX2 for autoimmune diseases (atopic dermatitis, urticaria), which received IND approval from both the Chinese CDE and US FDA in June 2025; a non-opioid painkiller program with biased mu-opioid receptor agonists; and metabolism programs (oral small molecule and peptide). AlphaMol generates revenue through co-development partnerships and out-licensing deals with pharmaceutical companies, though no commercial revenue is currently disclosed. The company completed a Series A financing round in August 2023 with investors including Huaqiang Capital, New Value Capital, and Shanghai Biomedical Industrial Equity Investment Fund.
Co-founders Dr. Shuguang Yuan and Prof. Horst Vogel anchor the scientific leadership, both recognized in Stanford's Top 2% Scientists globally. Dr. Yuan previously advanced two GPCR candidates to clinical development at Actelion, with one achieving FDA approval. Dr. Vogel is a full professor at EPFL with 40+ years of GPCR research and affiliations with Roche, Novartis, and Nestlé. AlphaMol has established research collaborations with the Max Planck Institute and Chinese Academy of Sciences, and its team won the 4th global GPCR-DOCK contest in 2022.
AlphaMol firmographics
Firmographics- Name
- AlphaMol
- Legal name
- ALPHAMOL SCIENCE LTD
- Website
- https://alphamol.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AlphaMol is a biopharmaceutical company operating across Switzerland and China that uses its proprietary AI-driven GPCR-Discovery platform to develop drug candidates for autoimmune, metabolism, and pain conditions, targeting pharmaceutical partnership and licensing deals.
- Ownership category
- akta.pro rank
AlphaMol industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where AlphaMol is headquartered
LocationHeadquarters
- HQ city
- Shenzhen
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
AlphaMol business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D
Revenue model
- Drug Development Partnerships and Licensing: AlphaMol generates revenue through co-development partnerships with pharmaceutical companies, out-licensing of drug candidates, and strategic collaborations. The company has progressed pipeline candidate AM-001 to IND approval and is advancing toward clinical trials, positioning for potential licensing deals or partnership structures with larger pharmaceutical companies.
- Series A Financing: Venture capital funding to support drug development and biotechnology research operations. Series A round completed in August 2023.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AlphaMol product offering
Product offeringCore offering
AlphaMol operates the GPCR-Discovery AI platform, an integrated software-driven drug discovery system for G-protein-coupled receptor (GPCR) drug development that combines molecular generation, virtual screening, lead optimization, molecular dynamics simulation, and binding energy prediction. In parallel, the company develops its own GPCR-targeted drug candidates (including AM-001 for autoimmune diseases, which has received IND approval from both Chinese CDE and the U.S. FDA) and engages in co-development partnerships and out-licensing of drug candidates with pharmaceutical and biotech companies.
Product overview
AlphaMol is an innovative biotech company combining computational biology, artificial intelligence, and cutting-edge biotechnology to advance GPCR (G-protein-coupled receptor) drug discovery. The company operates the GPCR-Discovery platform, a comprehensive AI-driven system with multiple integrated modules including GPCR-GPT (target identification), GPCR-3D (structure prediction), Alpha-screen (functional screening), GPCRomx (ligand selectivity prediction), GPCR-lead (lead optimization), and GPCR-XDC (peptide-drug conjugate design). Supporting tools include AlphaE for binding energy prediction. The company also develops in-house drug candidates, including AM-001 (an oral small molecule for autoimmune diseases now in clinical stages with IND approval). Pipelines span autoimmune, metabolism, and pain management therapeutic areas. AlphaMol has sites in Basel (Switzerland), Shanghai, and Shenzhen (China).
Differentiator
Problem solved
Functional benefit
Brands
- GPCRomx: Platform for predicting ligand selectivity in GPCR drug discovery
- GPCR-Discovery
- AlphaE
Products and services
- GPCR-Discovery Platform An AI-driven drug discovery platform specifically designed for GPCR drug development. The platform integrates computational biology, artificial intelligence, and biotechnology through multiple modules covering target identification, structure prediction, functional screening, ligand selectivity prediction, lead optimization, and peptide-drug conjugate design. It enables completion of preclinical drug discovery in 6–12 months versus traditional 12+ year timelines, with claimed 80–99% cost savings. Targeted at pharmaceutical and biotech companies and internal pipeline development.
- AM-001 Oral small molecule drug candidate developed by AlphaMol targeting the MRGPRX2 receptor for the treatment of autoimmune diseases, including atopic dermatitis and urticaria. Demonstrated >600-fold safety margin in GLP toxicology studies and verified in vivo efficacy in animal models. Received IND approval from both the Chinese CDE and the U.S. FDA in June 2025; intended for out-licensing and/or co-development with pharmaceutical partners.
Quantifiable outcome
- 80-99% cost savings in drug discovery time and finance compared to traditional methods
- +4 more outcomes
Companies that use AlphaMol
Customer profileSegments2 records
Ideal customer profiles1 record
AlphaMol technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature8 records
AlphaMol partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Max Planck Institute (Germany)coreAlphaMol Science Ltd collaborated with the Max Planck Institute in Germany to publish research on the serotonin-gated 5-HT3A receptor structure in The EMBO Journal. Professor Mikhail Kudryashev from Max Planck Institute served as corresponding author alongside AlphaMol scientists.
- CADD Center at Shenzhen Institutes of Advanced Technology, Chinese Academy of SciencescoreCollaboration on research article titled 'Structure of Tetrameric Forms of the Serotonin-gated 5-HT3A Receptor Ion Channel' published in The EMBO Journal as cover story.
- School of Pharmaceutical Sciences at Shenzhen University of Science and TechnologycoreCollaboration on research article titled 'Structure of Tetrameric Forms of the Serotonin-gated 5-HT3A Receptor Ion Channel' published in The EMBO Journal as cover story.
- Swiss Consulate General of Switzerland in GuangzhouminorAlphaMol co-founders were invited to attend dinner in honor of Swiss delegation visiting China on the 10th anniversary of the Bilateral Free Trade Agreement between China and Switzerland. Facilitated networking with Swiss Federal Council member Guy Parmelin and EPFL President.
- Swiss Federal Institute of Technology (EPFL)coreProfessor Horst Vogel, co-founder of AlphaMol, is a full professor at EPFL and maintains ongoing collaboration. Professor Martin Vetterli, President of EPFL, engaged with AlphaMol co-founders regarding bilateral scientific cooperation between China and Switzerland.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
AlphaMol competitors and assessment
Company assessmentDirect peers
- Schrödinger: Public AI-driven computational drug discovery platform offering molecular simulation, predictive modeling, and collaborative drug discovery programs. Highly comparable to AlphaMol in its use of physics-based and ML methods to accelerate preclinical drug design, though at much greater scale and breadth.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to identify novel therapeutic targets and advance an internal pipeline. Comparable to AlphaMol as a platform-plus-pipeline biotech using computational tools to derisk early-stage discovery, though focused on phenotypic screening across multiple target classes rather than GPCR specialization.
- Insitro: ML-enabled drug discovery company combining induced pluripotent stem cell biology, high-throughput experimentation, and AI to accelerate therapeutic development. Comparable to AlphaMol in applying AI to drug discovery pipelines, though differentiated by its wet-lab biology scale and disease-agnostic approach.
- XtalPi: China-based AI drug discovery company combining quantum physics, AI, and cloud computing for small molecule and crystal structure prediction. Highly comparable to AlphaMol as a fellow China-rooted AI drug discovery company with international operations and shared computational methodology, though XtalPi has broader therapeutic and partner scope.
- Exscientia: AI-driven precision medicine and drug discovery company that has brought multiple AI-designed candidates into clinical trials. Comparable to AlphaMol as a generative AI-first drug discovery company, with proven pharma partnerships (e.g., Bristol-Myers Squibb, Sanofi) but broader target coverage.
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and advance internal and partnered programs. Comparable to AlphaMol in applying AI to drug discovery with both platform and pipeline components, though with a broader target and indication focus.
- Atomwise: AI-driven small molecule drug discovery company using deep learning for structure-based design and virtual screening across multiple therapeutic areas. Comparable to AlphaMol in leveraging AI for hit identification and lead optimization, though without a GPCR-specific focus and with a stronger emphasis on pharma partnerships.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company building a computational platform for novel drug design with major pharma partnerships (Eli Lilly, Novartis). Comparable to AlphaMol in its AI-first approach to drug discovery, but operates at vastly greater scale, capital base, and target breadth as a subsidiary of a global technology leader.
- Roivant Sciences: Technology-enabled drug development company that acquires and advances clinical-stage therapeutic programs across multiple disease areas. Comparable to AlphaMol as a platform-centric drug developer pursuing partnership and licensing economics, though at a larger scale and later development stage across multiple modalities.
Emerging players
- Structure Therapeutics: Clinical-stage biotech focused on oral small molecule GPCR-targeted therapeutics for metabolic and cardiopulmonary diseases. Comparable to AlphaMol as a GPCR-focused drug developer, though Structure Therapeutics is more clinically advanced and focuses exclusively on oral small molecules rather than a broader AI platform approach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AlphaMol social profiles
Digital presenceAlphaMol financial estimates
Financial estimateRevenue estimate
Valuation estimate
AlphaMol leadership team
Management profileNumber of profiles
Profiles2 records
AlphaMol funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AlphaMol M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AlphaMol
What does AlphaMol do?
AlphaMol operates the GPCR-Discovery AI platform, an integrated software-driven drug discovery system for G-protein-coupled receptor (GPCR) drug development that combines molecular generation, virtual screening, lead optimization, molecular dynamics simulation, and binding energy prediction. In parallel, the company develops its own GPCR-targeted drug candidates (including AM-001 for autoimmune diseases, which has received IND approval from both Chinese CDE and the U.S. FDA) and engages in co-development partnerships and out-licensing of drug candidates with pharmaceutical and biotech companies.
Is AlphaMol a public or private company?
AlphaMol is a private company. It is classified as venture growth investor backed and is currently operating.
When was AlphaMol founded?
AlphaMol was founded in 2020. It employs 11 to 50 people.
Where is AlphaMol based?
AlphaMol is headquartered in Shenzhen, China, in the Asia region.
How does AlphaMol make money?
Two revenue lines are on record. Drug Development Partnerships and Licensing is the primary driver. The others are series A Financing.
Who are AlphaMol's main competitors?
Direct peers on record are Schrödinger, Recursion Pharmaceuticals, Insitro, XtalPi, Exscientia, BenevolentAI and Atomwise. Broad incumbents are Isomorphic Labs and Roivant Sciences. Structure Therapeutics is listed as an emerging player.
Does AlphaMol have an API?
No public API is recorded for AlphaMol.
What industry is AlphaMol in?
AlphaMol's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.